Beaufort Securities reissued their speculative buy rating on shares of Tiziana Life Sciences (LON:TILS) in a research report sent to investors on Tuesday morning. The firm currently has a GBX 400 ($5.36) price target on the biotechnology company’s stock.

Tiziana Life Sciences (LON TILS) opened at GBX 149.50 ($2.00) on Tuesday. Tiziana Life Sciences has a one year low of GBX 102.06 ($1.37) and a one year high of GBX 240 ($3.21).

Tiziana Life Sciences (LON:TILS) last released its earnings results on Friday, September 29th. The biotechnology company reported GBX (4.10) (($0.05)) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of GBX (2) (($0.03)) by GBX (2.10) (($0.03)).

COPYRIGHT VIOLATION WARNING: “Tiziana Life Sciences (TILS) Receives “Speculative Buy” Rating from Beaufort Securities” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/02/tiziana-life-sciences-tils-receives-speculative-buy-rating-from-beaufort-securities.html.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.

Receive News & Stock Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related stocks with our FREE daily email newsletter.